Clinical application of Dextran in improving postoperative hypercoagulability such as pulmonary embolism in patients with lung cancer

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000036812

Enrollment

Unknown

Registered

2020-08-25

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

Case series:Nil

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. It conforms to the diagnostic criteria of lung cancer in clinical Disease Diagnosis and Efficacy Evaluation criteria; 2. Pathological examination confirmed advanced lung adenocarcinoma; 3. Aged 18 to 80 years; 4. With complete clinical data, two groups of patients voluntarily accept genetic testing.

Exclusion criteria

Exclusion criteria: 1. Those who have failed other treatments such as immunotherapy, radiotherapy or pleural injection; 2. Expected survival < 6 months; 3. Patients with other organ dysfunction, severe cardiovascular and cerebrovascular diseases and other malignant tumors; 4. With relevant contraindications for treatment.

Design outcomes

Primary

Measure	Time frame
D-dimer;	—

Countries

China

Contacts

Public ContactLiao Ruomin

Shanghai General Hospital

minruoliao@sina.com+86 13916731182

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026